<?xml version="1.0" encoding="UTF-8"?>
<front-stub>
 <article-id pub-id-type="doi">10.5256/f1000research.18057.r41391</article-id>
 <title-group>
  <article-title>Reviewer response for version 1</article-title>
 </title-group>
 <contrib-group>
  <contrib contrib-type="author">
   <name>
    <surname>Kaufmann</surname>
    <given-names>Stefan H.E.</given-names>
   </name>
   <xref ref-type="aff" rid="r41391a1">1</xref>
   <role>Referee</role>
  </contrib>
  <aff id="r41391a1">
   <label>1</label>Department of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany
  </aff>
 </contrib-group>
 <author-notes>
  <fn fn-type="COI-statement">
   <p>
    <bold>Competing interests: </bold>I am co-inventor of a tuberculosis vaccine which is discussed in the text (VPM1002).
   </p>
  </fn>
 </author-notes>
 <pub-date pub-type="epub">
  <day>17</day>
  <month>12</month>
  <year>2018</year>
 </pub-date>
 <related-article related-article-type="peer-reviewed-article" id="d35e10178" ext-link-type="doi" xlink:href="10.12688/f1000research.16521.1" xmlns:xlink="http://www.w3.org/1999/xlink">Version 1</related-article>
 <custom-meta-group>
  <custom-meta>
   <meta-name>recommendation</meta-name>
   <meta-value>approve-with-reservations</meta-value>
  </custom-meta>
 </custom-meta-group>
</front-stub>
